Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHarvard Pilgrim adalimumab Prior Auth Policy Updat…
    Ask Trek AI about this page
    Modifiedharvard pilgrim health carePolicy N/A

    Adalimumab products — Prior authorization and medical necessity

    Customize your policy alerts

    Sign up for all harvard pilgrim health care policy alerts

    Know when harvard pilgrim health care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This guideline governs prior authorization and medical necessity criteria for coverage of adalimumab products (including multiple biosimilars and brands) for Harvard Pilgrim and affiliated commercial products; it applies to prescribers seeking coverage for members under the listed commercial and public plan products.

    Policy Summary
    Payerharvard pilgrim health care
    PolicyAdalimumab products — Prior authorization and medical necessity
    Policy CodePolicy N/A
    Change TypeFormulary and criteria revisions (material)
    Effective DateJul 1, 2026
    Last ReviewJun 9, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization with documentation of diagnosis, specialist prescriber, age, required prior therapy trials including a minimum three‑month trial of preferred Simlandi (unless contraindicated).
    SourceLink
    POLICY UPDATE CHANGES

    Added Starjemza as a prerequisite for Crohn's disease, plaque psoriasis, psoriatic arthritis, and ulcerative colitis to support the updated ustekinumab strategy.

    Simlandi moved from non-preferred to preferred status and Humira moved from preferred to non-preferred status.

    Members who initiated the requested medication by self-paying do not qualify as having an established clinical response and must be reviewed against initial approval criteria.

    For hidradenitis suppurativa, plaque psoriasis and psoriatic arthritis, initial approval limited to 6 months with reauthorization in 12‑month intervals; for ankylosing spondylitis, Crohn's disease, polyarticular JIA, rheumatoid arthritis, ulcerative colitis and uveitis, authorizations provided in 12‑month intervals.

    Multiple

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    FDA indications
    SimlandiPreferred product
    Often requiredSpecialist required
    Documented failuresPrior failures
    6 monthsInitial approval (HS/psoriasis/ PsA)
    Humira non‑preferredFormulary change

    Coverage Criteria by Indication

    Ankylosing Spondylitis — Initial and Reauthorization

    Covered when ALL of the following are met

    Initial Authorization: 1. Documented diagnosis of active ankylosing spondylitis; 2. Patient is at least 18 years of age or older; 3. Prescribed by a rheumatologist; 4. Documentation of history of failure to one (1) prescription-strength non-steroidal anti-inflammatory drug unless contraindicated (document drug, date and duration); 5. Documentation of history of failure to two (2) of the listed medications from the therapeutic categories (document drugs, dates and durations); 6. Documentation of history of failure to a minimum three (3) month supply of Simlandi, unless contraindicated (document date and duration of trial); 7. Documentation the patient is not receiving the requested medication in combination with another biologic drug or with a targeted synthetic oral small molecule drug.

    from chunks 8

    Reauthorization: 1. Documentation the patient has been established on the requested medication for at least 12 months; 2. Documented diagnosis of active ankylosing spondylitis; 3. Patient is at least 18 years of age or older; 4. Prescribed by a rheumatologist; 5. Documentation of clinically significant improvement or stabilization in clinical signs and symptoms of disease as determined by the prescriber; 6. Documentation the patient is not receiving the requested medication in combination with another biologic drug or with a targeted synthetic oral small molecule drug.

    from chunk 11

    Crohn's Disease — Initial and Reauthorization

    Covered when ALL of the following are met

    Initial Authorization: 1. Documented diagnosis of Crohn's disease; 2. Patient is at least 6 years of age or older; 3. Prescribed by a gastroenterologist; 4. Documentation of history of failure to one (1) of: corticosteroid, 5-aminosalycylate, 6-mercaptopurine, or methotrexate unless contraindicated (document drug, date and duration); 5. Documentation of history of failure to two (2) of the listed medications from the therapeutic categories (Interleukin antagonists, Janus kinase inhibitors, Tumor necrosis factors) (document drugs, dates and durations of trials); 6. Documentation of history of failure to a minimum three (3) month supply of Simlandi, unless contraindicated (document date and duration of trial); 7. Documentation the patient is not receiving the requested medication in combination with another biologic drug or with a targeted synthetic oral small molecule drug.

    from chunk 13

    Reauthorization: 1. Documentation the patient has been established on the requested medication for at least 12 months; 2. Documented diagnosis of moderately to severely active Crohn's disease; 3. Patient is at least 6 years of age or older; 4. Prescribed by a gastroenterologist; 5. Documentation of clinically significant improvement or stabilization in clinical signs and symptoms of disease as determined by the prescriber; 6. Documentation the patient is not receiving the requested medication in combination with another biologic drug or with a targeted synthetic oral small molecule drug.

    from chunk 14

    Hidradenitis Suppurativa — Initial and Reauthorization

    Covered when ALL of the following are met

    Initial Authorization: 1. Documented diagnosis of moderate to severe hidradenitis suppurativa; 2. Documentation of Hurley Stage II or III disease; 3. Patient is at least 12 years of age or older; 4. Prescribed by a dermatologist; 5. Documentation of history of failure to three (3) conventional treatments (local hygiene, weight reduction for obesity, soaps/antiseptics/antiperspirants, warm compresses, laser hair removal, smoking cessation, medical anti-inflammatory or antiandrogen therapy) unless contraindicated (document treatments, dates, durations); 6. Documentation of history of failure to a minimum three (3) month supply of Simlandi, unless contraindicated (document date and duration of trial); 7. Documentation the patient is not receiving the requested medication in combination with another biologic drug or with a targeted synthetic oral small molecule drug.

    from chunk 16

    Reauthorization: 1. Documentation the patient has been receiving the requested medication for at least six (6) months; 2. Documented diagnosis of moderate to severe hidradenitis suppurativa; 3. Patient is at least 12 years of age or older; 4. Prescribed by a dermatologist; 5. Submission of medical charts documenting a beneficial clinical response defined as improvement from baseline in at least one objective measure (e.g., Hurley staging, Sartorius, PGA, HSSI); 6. Submission of medical charts documenting improvement in at least one symptom (decreased pain or drainage, nodules, cysts); 7. Documentation the patient is not receiving the requested medication in combination with another biologic drug or with a targeted synthetic oral small molecule drug.

    from chunk 17

    Plaque Psoriasis — Initial and Reauthorization

    Covered when ALL of the following are met

    Initial Authorization: 1. Documented diagnosis of moderate to severe chronic plaque psoriasis; 2. Documentation of one of: ≥3% body surface area involvement, severe scalp psoriasis, or palmoplantar/facial/genital involvement; 3. Patient is at least 18 years of age or older; 4. Prescribed by a dermatologist; 5. Documentation of failure to a minimum three (3) month supply of at least one traditional systemic agent (methotrexate, cyclosporine, acitretin) or phototherapy unless contraindicated (document drug, date and duration); 6. Documentation of history of failure to two (2) of the listed medications from the therapeutic categories (Interleukin antagonists, PDE4 inhibitors, Tumor Necrosis Factors) (document drugs, dates and durations of trials); 7. Documentation of history of failure to a minimum three (3) month supply of Simlandi, unless contraindicated (document date and duration of trial); 8. Documentation the patient is not receiving the requested medication in combination with another biologic drug or with a targeted synthetic oral small molecule drug.

    from chunk 18

    Reauthorization: 1. Documentation the patient has been receiving the requested medication for at least six (6) months; 2. Documented diagnosis of moderately to severe plaque psoriasis; 3. Patient is at least 18 years of age or older; 4. Prescribed by a dermatologist; 5. Submission of medical charts documenting a beneficial clinical response defined as reduction in body surface area affected from baseline; 6. Submission of medical charts documenting improvement in at least one symptom (itching, redness, flaking, scaling, burning, cracking, or pain); 7. Documentation the patient is not receiving the requested medication in combination with another biologic drug or with a targeted synthetic oral small molecule drug.

    Initial Therapy (general) — Plaque Psoriasis initial

    Covered when ALL of the following are met

    Plaque Psoriasis initial: 1) Documented diagnosis of moderate to severe chronic plaque psoriasis; 2) Documentation of one of: >=3% BSA involvement, severe scalp psoriasis, or palmoplantar/facial/genital involvement; 3) Age >=18 years; 4) Prescribed by a dermatologist; 5) Failure to a minimum 3-month supply of at least one traditional systemic agent (methotrexate, cyclosporine, acitretin, or phototherapy) unless contraindicated (document drug, date and duration); 6) Documentation of history of failure to two (2) of the listed medications from the therapeutic categories (Interleukin antagonists, PDE4 inhibitors, TNF agents) (document drugs, dates and durations); 7) Documentation of history of failure to a minimum 3-month supply of Simlandi unless contraindicated (document date and duration of trial); 8) Documentation the patient is not receiving the requested medication in combination with another biologic drug or with a targeted synthetic oral small molecule drug.

    Document drugs, dates, and durations of trials

    Reauthorization (general) — Plaque Psoriasis reauth

    Covered when ALL of the following are met

    Plaque Psoriasis reauth: 1) Receiving requested medication for >=6 months; 2) Documented diagnosis of moderately to severe plaque psoriasis; 3) Age >=18 years; 4) Prescribed by a dermatologist; 5) Medical charts show beneficial clinical response defined as reduction in BSA from baseline; 6) Charts document improvement in at least one symptom (itching, redness, flaking, scaling, burning, cracking, or pain); 7) Documentation the patient is not receiving the requested medication in combination with another biologic drug or with a targeted synthetic oral small molecule drug.

    Initial Therapy (other indication block) — Polyarticular JIA initial

    Covered when ALL of the following are met

    Polyarticular JIA initial: 1) Documented moderately to severely active polyarticular juvenile idiopathic arthritis; 2) Age >=2 years; 3) Prescribed by a rheumatologist; 4) Failure to one traditional DMARD unless contraindicated (document drug, date and duration); 5) Documentation of history of failure to two (2) of the listed medications from the therapeutic categories (Interleukin antagonists, Janus kinase inhibitors, Selective T Cell Costimulation, TNF agents) (document drugs, dates and durations); 6) Documentation of history of failure to a minimum three (3) month supply of Simlandi unless contraindicated (document date and duration of trial); 7) Documentation the patient is not receiving the requested medication in combination with another biologic drug or with a targeted synthetic oral small molecule drug.

    Reauthorization (other indication block) — Polyarticular JIA reauth

    Covered when ALL of the following are met

    Polyarticular JIA reauth: 1) Documentation the patient has been established on the requested medication for at least 12 months; 2) Documented diagnosis of active moderately to severely active polyarticular juvenile idiopathic arthritis; 3) Age >=2 years; 4) Prescribed by a rheumatologist; 5) Documentation of clinically significant improvement or stabilization in clinical signs and symptoms of disease as determined by the prescriber; 6) Documentation the patient is not receiving the requested medication in combination with another biologic drug or with a targeted synthetic oral small molecule drug.

    Initial Therapy (other indication block) — Psoriatic arthritis initial

    Covered when ALL of the following are met

    Psoriatic arthritis initial: 1) Documented diagnosis of active psoriatic arthritis; 2) Documentation of one of: actively inflamed joints, dactylitis, enthesitis, axial disease, or active skin/nail involvement; 3) Age >=18 years; 4) Prescribed by a rheumatologist or dermatologist; 5) Documentation of failure to a minimum three (3) month supply of at least one DMARD unless contraindicated (document drug, date and duration); 6) Documentation of history of failure to two (2) of the listed medications from the therapeutic categories (Interleukin antagonists, Janus kinase inhibitors, PDE4 inhibitors, Selective T Cell Stimulators, TNF agents) (document drugs, dates and durations); 7) Documentation of history of failure to a minimum three (3) month supply of Simlandi unless contraindicated (document date and duration of trial); 8) Documentation the patient is not receiving the requested medication in combination with another biologic drug or with a targeted synthetic oral small molecule drug.

    Reauthorization (other indication block) — Psoriatic arthritis reauth

    Covered when ALL of the following are met

    Psoriatic arthritis reauth: 1) Receiving requested medication for at least six (6) months; 2) Documented diagnosis of active psoriatic arthritis; 3) Age >=18 years; 4) Prescribed by a rheumatologist or dermatologist; 5) Submission of medical charts documenting beneficial clinical response defined as improvement from baseline in at least one of: body surface area affected by psoriatic arthritis or total active joint count; 6) Submission of medical charts documenting improvement in at least one symptom (joint pain, morning stiffness, fatigue, swelling); 7) Documentation the patient is not receiving the requested medication in combination with another biologic drug or with a targeted synthetic oral small molecule drug.

    Initial Therapy (other indication block) — Rheumatoid Arthritis initial

    Covered when ALL of the following are met

    RA initial: 1) Documented diagnosis of moderately to severely active rheumatoid arthritis; 2) Age >=18 years; 3) Prescribed by a rheumatologist; 4) Documentation of history of failure to one (1) traditional DMARD unless contraindicated (document drug, date and duration); 5) Documentation of history of failure to two (2) of the listed medications from the therapeutic categories (Interleukin antagonists, Janus kinase inhibitors, Selective T Cell Stimulators, TNF agents) (document drugs, dates and durations); 6) Documentation of history of failure to a minimum three (3) month supply of Simlandi unless contraindicated (document date and duration of trial); 7) Documentation the patient is not receiving the requested medication in combination with another biologic drug or with a targeted synthetic oral small molecule drug.

    Reauthorization (other indication block) — Rheumatoid Arthritis reauth

    Covered when ALL of the following are met

    RA reauth: 1) Documentation the patient has been established on the requested medication for at least 12 months; 2) Documented diagnosis of moderately to severely active rheumatoid arthritis; 3) Age >=18 years; 4) Prescribed by a rheumatologist; 5) Documentation of clinically significant improvement or stabilization in clinical signs and symptoms of disease as determined by the prescriber; 6) Documentation the patient is not receiving the requested medication in combination with another biologic drug or with a targeted synthetic oral small molecule drug.

    Initial Therapy (other indication block) — Ulcerative Colitis initial

    Covered when ALL of the following are met

    Ulcerative colitis initial: 1) Documented diagnosis of moderately to severely active ulcerative colitis; 2) Patient is at least 5 years of age or older; 3) Prescribed by a gastroenterologist; 4) Documentation of history of failure to one (1) of: corticosteroid, 5-aminosalycylate, 6-mercaptopurine, or methotrexate unless contraindicated (document drug, date and duration); 5) Documentation of history of failure to two (2) of the listed medications from the therapeutic categories (Interleukin antagonists, Janus kinase inhibitors, S1P modulators, Tumor necrosis factors) (document drugs, dates and durations of trials); 6) Documentation of history of failure to a minimum three (3) month supply of Simlandi unless contraindicated (document date and duration of trial); 7) Documentation the patient is not receiving the requested medication in combination with another biologic drug or with a targeted synthetic oral small molecule drug.

    Reauthorization (other indication block) — Ulcerative Colitis reauth

    Covered when ALL of the following are met

    Ulcerative colitis reauth: 1) Documentation the patient has been established on the requested medication for at least 12 months; 2) Documented diagnosis of moderately to severely active ulcerative colitis; 3) Patient is at least 5 years of age or older; 4) Prescribed by a gastroenterologist; 5) Documentation of clinically significant improvement or stabilization in clinical signs and symptoms of disease as determined by the prescriber; 6) Documentation the patient is not receiving the requested medication in combination with another biologic drug or with a targeted synthetic oral small molecule drug.

    Initial Therapy (other indication block) — Uveitis initial

    Covered when ALL of the following are met

    Uveitis initial: 1) Documented diagnosis of non-infectious intermediate, posterior or panuveitis; 2) Prescribed by an ophthalmologist, ocular immunologist, or rheumatologist; 3) Documentation of history of failure to conventional therapy (periocular, intraocular, or systemic corticosteroids; immunosuppressants) unless contraindicated (document drug, date and duration); 4) Documentation of history of failure to a minimum three (3) month supply of Simlandi unless contraindicated (document date and duration of trial); 5) Documentation the patient is not receiving the requested medication in combination with another biologic drug or with a targeted synthetic oral small molecule drug.

    Reauthorization (other indication block) — Uveitis reauth

    Covered when ALL of the following are met

    Uveitis reauth: 1) Documentation the patient has been established on the requested medication for at least 12 months; 2) Documented diagnosis of non-infectious intermediate, posterior or panuveitis; 3) Prescribed by an ophthalmologist, ocular immunologist, or rheumatologist; 4) Documentation of clinically significant improvement or stabilization in clinical signs and symptoms of disease as determined by the prescriber; 5) Documentation the patient is not receiving the requested medication in combination with another biologic drug or with a targeted synthetic oral small molecule drug.

    Humira (adalimumab) Additional — additional requirement for Humira products

    Applies in addition to the coverage criteria for the requested indication

    Humira biosimilars failure: Documentation of history of failure to Adalimumab-aacf, Adalimumab-aaty, Adalimumab-adaz, Adalimumab-adbm, Adalimumab-fkjp, Adalimumab-ryvk, Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Yuflyma, and Yusimry, unless contraindicated (document drugs, dates and duration of trials).

    Applies in addition to indication-specific coverage criteria

    Authorization duration and initial vs reauthorization — coverage duration and review rules

    Coverage duration and review rules

    Duration and review rules: For hidradenitis suppurativa, plaque psoriasis, and psoriatic arthritis: initial approval for six (6) months; reauthorization provided in 12-month intervals. For ankylosing spondylitis, Crohn's disease, polyarticular juvenile idiopathic arthritis, rheumatoid arthritis, ulcerative colitis, and uveitis: authorizations provided in 12-month intervals. Members who have received less than the specified prior therapy duration or who are restarting therapy are reviewed under Initial Authorization Criteria. Members new to the plan stable on the requested medication should be reviewed against Initial Authorization Criteria.see intro

    Applies to authorization processing

    Coverage will not be approved when the requested adalimumab product is being used concurrently with another biologic drug or with a targeted synthetic oral small molecule drug. Providers must document that the patient is not receiving the requested medication in combination with another biologic or targeted synthetic oral small molecule drug as a condition of authorization (see indication-specific criteria).

    This prohibition applies to initial authorizations and reauthorizations across the listed indications and is included among the required documentation for prior authorization.

    Documentation that a member is a social drinker does not constitute a medically acceptable contraindication to methotrexate therapy and therefore does not justify bypassing required prior therapy steps that include methotrexate where indicated.

    When methotrexate is a required prior agent, providers should document a true contraindication or clinically significant adverse effect to methotrexate — simple documentation of social alcohol use alone is insufficient for authorization exceptions.

    The plan considers documentation that a member is a social drinker to be inadequate as a medically acceptable contraindication or clinical inappropriateness for therapies (for example, methotrexate) that are required by the policy prior to biologic therapy.

    Providers seeking an exception must demonstrate a documented contraindication or clinically significant adverse reaction to the agent in question; social alcohol use by itself will not meet that standard.

    Members who began the requested medication through samples, free goods, similar offerings, or by self-paying directly do not qualify as having an established clinical response for purposes of reauthorization. Such members should be reviewed under the Initial Authorization Criteria.

    Providers must submit documentation of how therapy was initiated and the duration of prior therapy; if initiation was via samples/free goods/self-pay, the member must meet initial prior-therapy and step requirements rather than being treated as an established responder.

    Initial Authorization Requirements

    Initial therapy requirements — overarching initial authorization requirements

    Initial authorization criteria vary by indication but commonly require the following

    General initial requirements: Diagnosis per indication; age threshold per indication; prescribed by the specialist indicated for the condition; documentation of failure to designated conventional or listed biologic/targeted therapies as specified per indication (document drug names, dates, and durations); documentation of history of failure to a minimum three (3) month supply of the preferred adalimumab product Simlandi unless contraindicated (document date and duration); and documentation the patient is not receiving the requested medication in combination with another biologic drug or with a targeted synthetic oral small molecule drug.

    Initial Authorization — per-indication initial authorization requirements

    Initial authorization requirements per indication

    Initial therapy general: Initial authorization requires documented diagnosis, appropriate specialist prescriber, age criteria per indication, failure to specified traditional/systemic agents where required, failure to two medications from listed therapeutic categories (or as specified), and a minimum three (3) month trial of Simlandi unless contraindicated; the requested medication must not be used in combination with another biologic or targeted synthetic oral small molecule drug.

    Reauthorization / Continuation Requirements

    Reauthorization requirements by indication — demonstration of continued benefit per indication

    Reauthorization requires demonstration of continued benefit and documentation per indication

    Continuation general: For indications with 12-month reauthorization intervals: documentation the patient has been established on the requested medication for at least 12 months and documentation of clinically significant improvement or stabilization in clinical signs and symptoms as determined by the prescriber; patient must not be receiving the requested medication in combination with another biologic drug or with a targeted synthetic oral small molecule drug.
    Hidradenitis Suppurativa and Plaque Psoriasis and Psoriatic Arthritis: For indications with 6-month initial approvals (hidradenitis suppurativa, plaque psoriasis, psoriatic arthritis): documentation the patient has been receiving the requested medication for at least six (6) months and submission of medical charts demonstrating objective and symptomatic improvement from baseline as specified per indication; patient must not be receiving the requested medication in combination with another biologic drug or with a targeted synthetic oral small molecule drug.

    Reauthorization — per-indication reauthorization requirements

    Therapeutic Step Requirements and Product Strategy

    StepRequirementDuration / Notes
    1
    Trial of the preferred adalimumab product Simlandi is required prior to coverage of other adalimumab products (document date and duration of a minimum three-month supply unless contraindicated)
    Minimum 3 months trial of Simlandi; document drug, dates, and duration of trial. Applies across multiple indications per policy (see indication-specific criteria).
    StepRequirementApplicable Indications / Notes
    1
    Documentation of history of failure to specified agents across therapeutic categories; typically requires failure to two medications from the listed classes (only one required if only one is available for a category). Document drug names, dates, and durations of trials.
    {"text":"Applies to many indications (examples include plaque psoriasis, Crohn\'s disease, polyarticular JIA, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, hidradenitis suppurativa, uveitis). Specific class lists and agents are defined per indication in the policy.","status":""}
    StepRequirementAffected Indications / Notes
    1
    Added Starjemza (preferred ustekinumab) as a prerequisite product for certain indications to align with the ustekinumab product strategy; providers must meet ustekinumab prerequisites where specified in the policy (nonbiologic prerequisites and disease severity requirements remain as indicated).
    {"text":"Applied to Crohn\'s disease, plaque psoriasis, psoriatic arthritis, and ulcerative colitis per the June 9, 2026 revision; Yesintek and Starjemza are designated preferred ustekinumab products. See indication-specific sections for full prerequisite lists.","status":""}

    Provider Requirements, Documentation, and Denial Risks

    Prior Authorization

    Prior authorization required for adalimumab products

    Prior authorization is required for all adalimumab products for the listed Harvard Pilgrim and Tufts commercial and specified public plan products; contact the plan using the fax numbers provided when submitting authorization requests.

    Documentation Required

    Required prior authorization documentation and prescriber details

    Submit documentation that includes the member's diagnosis, prescriber specialty, age, detailed prior therapy trials (drug names, dates, durations), and evidence the patient is not receiving the requested medication in combination with another biologic or targeted synthetic oral small molecule drug.

    • Prescriber specialty (e.g., rheumatologist, dermatologist, gastroenterologist, ophthalmologist/ocular immunologist) as specified per indication
    • Age per indication (examples: ≥18 years for plaque psoriasis; ≥6 years for Crohn's; ≥12 years for hidradenitis suppurativa; ≥2 years for polyarticular JIA)

    Coding and Key Clinical Values

    Codesmixed
    No codes listed
    Codesmixed
    No codes listed
    Plaque Psoriasis BSA — >= 3% body surface area
    Threshold>= 3% body surface area
    Alternative criteriaSevere scalp, palmoplantar, facial, or genital involvement may qualify instead of BSA
    Documentation noteDocument the percent BSA and/or site-specific involvement in the medical record
    Age minimum — patient is at least 2 years of age or older
    Minimum agePatient is at least 2 years of age or older
    ApplicationApplies to age thresholds specified across indications (see indication-specific criteria for higher minimums)

    Preferred Product and Biosimilar Strategy

    Billing Rule

    Simlandi preferred; 3-month trial required

    Simlandi is the preferred adalimumab product; a minimum three-month trial of Simlandi is required (unless contraindicated) prior to approval of other adalimumab products.

    • Document the date and duration of at least a 3-month Simlandi trial unless contraindicated
    Billing Rule

    Humira-specific requirement: document failure to listed biosimilars/brands

    For Humira (adalimumab) products, documentation of failure to the listed adalimumab biosimilars and brands is required in addition to meeting the indication-specific criteria.

    • Document failure to the listed biosimilars/brands (Adalimumab-aacf, -aaty, -adaz, -adbm, -fkjp, -ryvk, Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Yuflyma, Yusimry) with dates and durations

    Key Definitions and Product Lists

    Adalimumab products — list of adalimumab biosimilars and brands included
    Included productsAdalimumab-aacf, Adalimumab-aaty, Adalimumab-adaz, Adalimumab-adbm, Adalimumab-fkjp, Adalimumab-ryvk
    Brand namesAbrilada, Amjevita, Cyltezo, Hadlima, Hulio, Humira, Hyrimoz, Idacio, Yuflyma, Yusimry
    Preferred productSimlandi (adalimumab-ryvk) is the preferred adalimumab product and requires prior authorization
    Moderate to severe plaque psoriasis — definition: >=3% BSA or special site involvement
    DefinitionModerate to severe plaque psoriasis: documented diagnosis with >=3% BSA involvement or severe scalp, palmoplantar, facial, or genital involvement
    Prescriber requirementPrescribed by a dermatologist (per plaque psoriasis criteria)

    Background

    Adalimumab is a tumor necrosis factor (TNF) blocker approved for multiple immune-mediated inflammatory conditions listed in this guideline. The policy covers branded adalimumab and numerous biosimilar formulations.

    Multiple adalimumab biosimilars and brand products are included in the guideline’s scope (for example, Simlandi and Humira among others), and the policy specifies a preferred biosimilar strategy in which a minimum three-month trial of the preferred product Simlandi is required prior to coverage of other adalimumab products unless contraindicated.

    The guideline also records recent formulary and strategy updates, including movement of Simlandi to preferred status and Humira to non-preferred status, and the addition of product-specific prerequisites in support of the ustekinumab strategy (e.g., Starjemza).

    Policy Revision History

    2026-06-09material_changeLatest

    Added Starjemza as a prerequisite for Crohn's disease, plaque psoriasis, psoriatic arthritis, and ulcerative colitis to support the updated ustekinumab strategy; Yesintek and Starjemza designated as preferred ustekinumab products.

    2025-12-09formulary_update

    Simlandi moved from non-preferred to preferred status and Humira moved from preferred to non-preferred status (effective 2026-03-01).

    2024-10-14
    Policy Summary
    Payerharvard pilgrim health care
    PolicyAdalimumab products — Prior authorization and medical necessity
    Policy CodePolicy N/A
    Change TypeFormulary and criteria revisions (material)
    Effective DateJul 1, 2026
    Last ReviewJun 9, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization with documentation of diagnosis, specialist prescriber, age, required prior therapy trials including a minimum three‑month trial of preferred Simlandi (unless contraindicated).
    SourceLink
    On This Page
    Coverage Criteria by IndicationInitial Authorization RequirementsReauthorization / Continuation RequirementsTherapeutic Step Requirements and Product StrategyProvider Requirements, Documentation, and Denial RisksCoding and Key Clinical ValuesPreferred Product and Biosimilar StrategyKey Definitions and Product ListsBackgroundPolicy Revision History

    from chunk 19

    Specific medications, age thresholds, and additional disease-specific requirements are specified in the indication-specific sections of the policy.

    Initial Authorization Criteria (reference) — operational initial review guidance

    Initial authorization review

    Initial authorization: A patient who has received less than the specified prior therapy duration for the indication or who is restarting therapy with the requested drug is reviewed under Initial Authorization Criteria. Members new to the plan or members who initiated therapy using samples, free goods, or by self-paying directly should be reviewed against Initial Authorization Criteria to confirm the requirements are met.time-based

    Initial Authorization Criteria are defined in the indication-specific sections of the policy.

    Reauthorization requirements per indication

    Reauthorization requires documentation the patient has been established on the requested medication for the interval specified for the condition (6 or 12 months as applicable), documentation of clinically significant improvement or stabilization in clinical signs and symptoms as determined by the prescriber, appropriate specialist prescriber, indication and age criteria as per initial authorization, and documentation the patient is not receiving the requested medication in combination with another biologic drug or with a targeted synthetic oral small molecule drug.6 or 12 months depending on indication

    Medical charts should demonstrate improvement measures appropriate to the indication (e.g., BSA reduction for plaque psoriasis; joint counts for psoriatic arthritis; objective HS measures),

    Reauthorization rules — reauthorization intervals

    Reauthorization intervals

    Reauthorization intervals: Reauthorization will be provided in 12-month intervals for most listed indications. For hidradenitis suppurativa, plaque psoriasis, and psoriatic arthritis: initial approval is for six (6) months and subsequent reauthorization is provided in 12-month intervals. Members who have received less than the specified prior therapy duration or who are restarting therapy are reviewed under Initial Authorization Criteria.time-based

    Continuation requires meeting the reauthorization documentation requirements described elsewhere in the policy

  1. Document drug name, dates, and duration for all prior therapy trials including a minimum 3-month trial of Simlandi unless contraindicated
  2. Statement that the member is not receiving the requested medication with another biologic or targeted synthetic oral small molecule drug
  3. Prior Authorization

    Prior authorization duration and reauthorization intervals

    Initial authorization durations vary by indication: hidradenitis suppurativa, plaque psoriasis, and psoriatic arthritis are initially authorized for 6 months; other listed indications (e.g., ankylosing spondylitis, Crohn's disease, polyarticular JIA, RA, ulcerative colitis, uveitis) are authorized in 12-month intervals. Members with less than the specified prior therapy duration or restarting therapy are reviewed under initial authorization criteria.

    • Hidradenitis suppurativa, plaque psoriasis, psoriatic arthritis: initial approval = 6 months; reauthorization in 12-month intervals
    • Ankylosing spondylitis, Crohn's disease, polyarticular JIA, rheumatoid arthritis, ulcerative colitis, uveitis: authorizations provided in 12-month intervals
    • Members new to the plan or restarting therapy are reviewed under Initial Authorization Criteria
    Step Therapy

    Step requirement: trial of preferred Simlandi (≥3 months)

    For most indications, the member must have documented failure to specified classes/agents and must have trialed the preferred product Simlandi for a minimum three-month supply prior to approval of other adalimumab products, unless contraindicated.

    • Document failure to required traditional/systemic agents and two medications from listed therapeutic categories (document drugs, dates, durations)
    • Document a minimum 3-month trial of Simlandi unless contraindicated (note date and duration)
    Step Therapy

    Therapeutic step: failures across classes and traditional agents

    Therapeutic step requires documented failure to specified traditional systemic agents and failures across multiple therapeutic classes (typically two medications from the listed categories) in addition to the Simlandi trial.

    • Fail at least one traditional/systemic agent (examples listed per indication: methotrexate, cyclosporine, acitretin, phototherapy, DMARDs)
    • Fail two medications from listed therapeutic categories (interleukin antagonists, JAK inhibitors, TNF agents, PDE4 inhibitors, S1P modulators, etc.) — document drugs, dates, durations
    • Fail a minimum 3-month supply of Simlandi unless contraindicated
    Step Therapy

    Product-specific prerequisite: Starjemza added for some indications

    For certain indications (Crohn's disease, plaque psoriasis, psoriatic arthritis, and ulcerative colitis) Starjemza (preferred ustekinumab product) has been added as a prerequisite in the ustekinumab product strategy; follow the nonbiologic and disease severity prerequisites noted elsewhere in the policy.

    • Yesintek and Starjemza are referenced as preferred ustekinumab products in the policy revision
    • Starjemza added as a prerequisite for coverage evaluation in specified indications
    Documentation Required

    Provider submission: include diagnosis, age, specialty, and prior therapy details

    When submitting an authorization request, providers must include diagnosis, patient age, prescriber specialty, and complete prior therapy details (drug names, dates, durations), including documentation of a Simlandi trial when required.

    • Include prescriber specialty specified by indication (e.g., dermatologist for plaque psoriasis, gastroenterologist for Crohn's/ulcerative colitis)
    • Provide precise dates and durations for prior therapy trials and Simlandi trial (if applicable)
    Documentation Required

    Required documentation for initial authorization and reauthorization

    Required documentation for initial requests and reauthorization includes the diagnosis, prescriber specialty, age, prior therapy trials with drug names/dates/durations, and for reauthorization, medical chart evidence of clinical improvement or stabilization compared to baseline as specified by indication.

    • Initial requests: document diagnosis, age, prescriber specialty, prior therapy trials (drug, date, duration)
    • Reauthorization: submit medical charts showing beneficial clinical response (e.g., reduction in BSA for plaque psoriasis, objective measures for hidradenitis suppurativa, improvement in joint counts for psoriatic arthritis)
    • Always document that the patient is not receiving concomitant biologic or targeted synthetic oral small molecule therapy
    Documentation Required

    Document prior initiation and duration to determine review pathway

    Document whether the member previously initiated the requested medication and the duration of prior therapy to determine if the case should be reviewed under initial authorization criteria or continuation/reauthorization rules.

    • If member initiated therapy via plan-covered fills and has met the duration thresholds, consider reauthorization criteria
    • If member has received less than the required duration or is restarting therapy, review under Initial Authorization Criteria
    Denial Risk

    Denial risk if required documentation is missing

    Coverage may be denied if required documentation is missing, including the diagnosis, specialist prescriber, documentation of prior therapy trials (including trial of Simlandi where required), age requirements, or evidence the patient is not receiving concomitant biologic or targeted synthetic oral small molecule therapy.

    • Missing dates/durations for prior therapy trials or absence of a documented Simlandi trial (when required) risks denial
    • Lack of prescriber specialty documentation or age not meeting indication thresholds can lead to denial
    Denial Risk

    Established response not recognized for samples/free goods/self-pay initiation

    Members who initiated the requested medication using samples, free goods, or by self-paying directly do not qualify as having an established clinical response and should be reviewed against initial authorization criteria; lack of qualifying established response may result in denial.

    • If therapy was started via samples, free goods, or self-pay, submit full initial authorization documentation — these starts are not accepted as established response
    • Administrative update clarifies self-pay initiation does not confer established status
    Note
    Coding/source noteAge statements appear in the policy codes/background section
    Billing Rule

    Formulary status changes: Simlandi preferred; Humira non-preferred

    Formulary status changed: Simlandi moved from non-preferred to preferred status and Humira moved from preferred to non-preferred status.

    Documentation requirementDocument BSA percent or site-specific severity in the medical record
    Definition of Pharmacy Medical Necessity Guidelines
    PurposePharmacy Medical Necessity Guidelines determine coverage for plan benefits and summarize the basis for coverage decisions
    ContentThey include concise clinical coverage criteria based on literature review, expert consultation, FDA and agency policies, and national standards
    Use in adjudicationGuidelines inform case-by-case coverage decisions but do not guarantee payment; benefit documents govern for self-insured plans
    policy_revision

    Updated provider requirements to prevent duplicative targeted immunomodulator therapy and specified initial approval durations and reauthorization intervals by indication (6 months initial for hidradenitis suppurativa, plaque psoriasis, psoriatic arthritis; 12 months initial for other listed indications).

    2025-06-10review

    Reviewed by the Pharmacy & Therapeutics Committee (effective 2025-09-01).